* Stratos Global, a Bethesda international telecommunications company, earned $5.4 million (11 cents a share) on $95.1 million in revenue during the second quarter, down 34 percent from net income of $8.2 million (17 cents) on $108.2 million in revenue during the corresponding quarter a year ago. For the six months ended June 30, the company earned $12.1 million (24 cents) on $187.3 million in revenue, down 21 percent from net income of $15.3 million (31 cents) on $203.8 million in revenue during the first half of 2003. The company also revised its earnings guidance for 2004 downward to between $80 million and $85 million, from its previous estimate of $85 million to $95 million. Forecast revenue for 2004 was also reduced to between $375 million and $390 million, from a previous estimate of $400 million to $430 million. The company attributed the lower earnings and estimates to lower-than-expected government and military expenditures for its services, including satellite phones. Shares of Stratos closed at $9.32 on the Toronto Stock Exchange, down 63 cents.
* Celera Genomics, a Rockville biotech company, announced a joint research project with Celera Diagnostics and General Electric's global research division. The research collaboration is intended to support GE's development of novel imaging agents for cancer that selectively target cell surface proteins that Celera Genomics has identified to be associated with the disease. Celera Diagnostics, based in Alameda, Calif., is a joint venture between Celera Genomics and Applied Biosystems. Both are tracking stock subsidiaries of Applera.
* NexTone Communications, a Gaithersburg company that makes session management products for Internet services, said it closed $10 million in funding in a round led by BCE Capital, the venture arm of Bell Canada Enterprises. David McCarthy of BCE Capital will join the NexTone board of directors. NexTone plans to use the funding for product development and expanded marketing and sales initiatives. Other investors include Core Capital, Mid-Atlantic Venture Funds, Safeguard Scientifics, Delmag Ventures and Blue Rock Capital.
* Versar, a Springfield professional services company, won a five-year, $10 million contract from the Office of Pollution Prevention and Toxics at the Environmental Protection Agency. Versar will conduct exposure and risk assessments for toxic chemicals, develop exposure assessment methodologies and support the review of new and existing chemicals.
Compiled from reports by Washington Post staff writers.